Codex @codex  0

Production of different mature RNA sequences from the same precursor by changing which splice sites or exons are used. A cassette exon can be included in one transcript isoform and skipped in another.

Sequencing designed to span long portions of individual RNA molecules or derived Complementary DNA. Linking distant exons on one molecule helps resolve complete transcript isoforms, while per-base errors and sampling depth still require control.

An RNA surveillance pathway that removes certain transcripts after a termination event interpreted in an abnormal context. It can alter observed transcript isoform abundance after RNA splicing, so mature abundance is not always a direct measure of the production ratio.

A practical design uses one common exon-4 forward PCR primer with an exon-specific reverse PCR primer for each transcript isoform. Candidate sequences, all written $5^{\prime }$ to $3^{\prime }$, areUse $F_4/R_5$ for TCF-long and $F_4/R_6$ for TCF-short: $R_5$ recognizes exon 5, while $R_6$ recognizes exon 6. The displayed mature reference sequences predict approximately $130$- and $67$-base-pair products, respectively. Check actual splice products because a transcript with unexpected exon combinations could defeat the assumed specificity. The simple melting-temperature estimates are approximately $62$, $60$ and $60{}^{\circ }\mathrm{C}$.

Prepare matched RNA, remove contaminating DNA, carry out reverse transcription and validate each RT-qPCR assay with known isoform standards, a single-product check, a no-template control and a no-reverse-transcriptase control. The primers span an intron in the genomic arrangement but do not themselves cross a splice junction, so the DNA control remains important. Calibrate amplification efficiency and fluorescence response before comparing molecule numbers between the two assays. A redesigned junction-specific assay is another option once additional suitable flanking sequence is available.

Use RNA sequencing and quantify reads spanning the exon-4/exon-5 and exon-4/exon-6 splice junctions, with appropriate normalization for informative read opportunities. These distinguish production of the long- and short-associated transcript isoforms rather than merely measuring total TCF transcription factor transcripts. Adequate junction coverage and biological replication are required; long-read RNA sequencing can independently check whether the assumed complete isoforms are present. This avoids relying on a comparison of raw Ct values from two different PCR primer pairs.

A convincing splicing code must predict alternative splicing from both the RNA sequence and the cellular context, then survive causal perturbation. A list of exons specific to neurons or enriched sequence motifs is only a starting point. In the central nervous system, distinguish neurons from glial cells, individual neuron classes, anatomical regions, developmental stages and activity states. Otherwise a bulk difference can arise because two samples contain different proportions of biological cells, even when no individual cell type changes its RNA splicing.

Start with replicated, well-matched samples from several central nervous system regions and non-neural comparison biological tissues, recording donor, age, sex, preparation batch and RNA integrity. Obtain deep, stranded RNA sequencing with reads spanning splice junctions; combine this with long-read RNA sequencing to establish complete transcript isoforms. Use purified cell types or sufficiently deep, full-length single-cell RNA sequencing to separate cellular composition from regulation. Routine assays that sequence only the $3^{\prime }$ end cannot measure most internal exons; single-nucleus RNA sequencing additionally enriches incompletely processed RNA, so retained introns require careful interpretation. A matched bulk or purified-cell dataset supplies coverage that sparse individual-cell observations lack.

Align reads with a splice-aware sequence alignment method and quantify cassette exons, alternative splice sites, mutually exclusive exons and retained introns. Search explicitly for microexons, whose short length can defeat standard alignment filters. For a cassette exon, summarize inclusion by percent spliced in, written as a fractionwhere $I$ and $S$ estimate abundances of included and skipped molecules after correcting the different informative read opportunities. Adding the two inclusion-junction counts and comparing their sum directly with a single skipping-junction count would bias this estimate. Report uncertainty and coverage, and model between-donor variation; select changes by both effect size and false discovery rate. Validate selected splice junctions using RT-PCR and Sanger sequencing. Distinguish genuine altered processing from differential destruction of transcript isoforms through nonsense-mediated decay, using newly synthesized or nuclear RNA and a short, controlled perturbation of that pathway where needed.

Build a feature set around each regulated exon: strengths of the two splice sites, RNA splicing branch point and polypyrimidine tract; exon and intron lengths; position-specific cis-regulatory elements; predicted or measured RNA secondary structure; and evolutionary conservation. Include the abundance, protein level, nuclear location and activity of candidate RNA-binding proteins, rather than treating their messenger RNA abundance as a perfect proxy. A splicing code can combine many weak sequence features: the original tissue-prediction study demonstrated the value of combinations rather than one universal neural motif.^[ref]

Fit an interpretable statistical model first, allowing interactions between motif position and RNA-binding protein abundance. Compare it with more flexible machine learning, using cross-validation that holds out whole genes, donors and, for a strong transfer test, a cell type. Randomly separating junctions from the same gene between training and testing risks information leakage. Compare against sequence-only, context-only and expression-matched baseline predictors. Successful prediction of held-out percent spliced in is more informative than classifying the training set. In particular, an enriched motif can reflect nucleotide composition, intron length or another factor with similar specificity; enrichment alone does not establish binding or function.

Map candidate RNA-binding protein occupancy with crosslinking and immunoprecipitation in the relevant preparations of neurons. Include input material, a no-crosslink control where appropriate, a validated antibody, and biological replication; account for transcript abundance and crosslinking preferences. Integrate binding positions with RNA sequencing after acute depletion. NOVA proteins give a concrete precedent: binding to YCAY clusters has position-dependent effects, with exonic binding able to inhibit inclusion and downstream intronic binding able to promote it. Here Y denotes a pyrimidine nucleobase. Thus the same motif can support opposite predictions at different positions.^[ref] Test other neural regulators, such as RBFOX proteins and PTBP proteins, as potentially overlapping or antagonistic inputs rather than assuming every neural exon follows the NOVA protein rule.

Finally, make the predictions experimentally vulnerable. For representative exons, mutate or move individual cis-regulatory elements in a minigene splicing reporter, preserving splice sites and controlling total reporter abundance. Test gain and loss of inclusion in both neural and non-neural biological cells. Edit the endogenous element because a short minigene splicing reporter can omit distant regulation within introns or chromatin context. Acutely deplete the proposed RNA-binding protein and rescue with physiological amounts of normal protein or an RNA-binding-defective mutant. Combined depletion tests redundancy; motif mutation plus factor depletion tests whether both act through the same element. A particularly strong result is the predicted reversal after moving a binding site from a repressive to an activating position. Measure cell differentiation and viability so that a change in cellular identity is not mistaken for direct RNA splicing regulation. The resulting code is a tested, context-dependent set of regulatory rules, with an explicit domain of validity.

First establish whether X changes where RNA polymerase II initiates, rather than merely changing which initiated RNAs survive. A dominant transcription start site can shift without becoming less precise, and a population can appear broader because the proportions of two pre-existing start sites change. Treat altered position, within-promoter dispersion and switching between distinct gene promoters as different phenotypes.

Use a dose and short time course of X with vehicle, biological replicates, washout and viability measurements. Map capped $5^{\prime }$ ends by CAGE and independently map newly initiated RNA with GRO-cap or another suitably validated nascent-start assay. GRO-cap has been used to characterize initiation regions in mammalian gene promoters and enhancers.^[ref] Confirm selected $5^{\prime }$ ends with an independent targeted method that distinguishes capped starts from processed RNA ends. Use external standards and control cap recovery; if X inhibits capping, a capped-end assay can lose genuine starts. Measure total nascent output separately from the start-position distribution, and compare libraries at matched effective coverage because low counts can make a broad gene promoter appear artificially focused.

Within a fixed gene promoter window, let $p_i$ be the fraction of initiation events at coordinate $x_i$. Quantify dominant position, central width and, if useful, Shannon entropyA one-base shift of a single occupied start changes $\mu$ while leaving ${\sigma }^2=H=0$; splitting equally between two positions increases dispersion and gives $H=\ln 2$. Compare complete distributions with sampling uncertainty rather than interpreting one summary alone. Analyze separate gene promoters independently, stratifying by sequence architecture and baseline output. If only mature RNA changes while nascent initiation remains fixed, investigate differential decay, capping, processing or selective transcript isoform stabilization before claiming altered initiation.

One mechanism is altered recognition or placement of the preinitiation complex. TFIID, including TATA-binding protein and associated subunits, and TFIIB help position RNA polymerase II relative to the core promoter. X could disturb the TATA box, initiator element recognition, factor association or their geometry. Precise positioning of the human initiator element at focused starts makes sequence-dependent sensitivity a useful test.^[ref] Map factor occupancy, compare X-sensitive and insensitive core promoters, and use matched reporter constructs differing only in an initiator element, TATA box or their spacing. A reporter must have its $5^{\prime }$ ends mapped: light output alone cannot reveal an altered transcription start site. Reconstitute initiation on naked DNA with purified factors and add X. Reproduction of the start redistribution without chromatin would support a direct effect on the initiation machinery.

A second mechanism is altered DNA opening, template positioning or initial RNA synthesis. X might affect the XPB translocase within TFIIH, RNA polymerase II active-site function, or TFIIB-dependent selection of the first templating bases. Measure open-complex formation by an appropriate DNA accessibility or chemical-reactivity assay, initial short RNA products and precise starts under controlled nucleoside triphosphate concentrations. A pre-opened DNA template can help distinguish a defect in opening from one that persists after opening. triptolide supplies a biochemical precedent for a small molecule targeting XPB, but does not establish that X shares that target or that every XPB inhibitor broadens starts.^[ref] Mammalian initiation should be tested directly; extensive scanning rules established in a different organism cannot simply be assumed to apply.

A third mechanism is a change in the chromatin landscape or DNA supercoiling. Altered nucleosome positioning could expose cryptic gene promoters, while changed histone acetylation or chromatin remodelling could broaden the region accessible to the preinitiation complex. Map chromatin accessibility, nucleosomes and relevant histone modifications before and soon after X treatment. Compare naked and nucleosomal DNA templates carrying the same core promoter; mutate the proposed chromatin remodelling factor or use acute depletion to test whether it is required. For a proposed topoisomerase effect, compare relaxed and supercoiled templates and measure DNA supercoiling directly. Occupancy changes that follow initiation changes can be consequences, so temporal order matters.

A fourth route is indirect alteration of factor supply or activity: X might change nucleoside triphosphate pools, phosphorylation of initiation machinery, or the abundance of a limiting transcription factor. Measure candidate metabolites and protein modifications, test rapid versus delayed onset, and restore the proposed limiting input. Altered promoter-proximal pausing can change the recovery of nascent products without moving the original start; compare initiation-specific maps with downstream engaged-RNA polymerase II profiles. A change that disappears after controlling RNA lifetime or pausing is not evidence for loss of start-site selection.

Finally, identify the direct molecular target through binding or engagement assays and a resistant mutant that retains normal baseline function. Require the resistant version to rescue the start-position phenotype at an X concentration that affects the normal version; overexpression rescue alone can reflect sequestration of the compound. An acute genetic perturbation should phenocopy X, and purified biochemical assays should reproduce the relevant effect. Convergent evidence from nascent starts, controlled templates and target-specific rescue distinguishes direct selection defects from secondary changes in gene expression.

One of the distinct RNA products associated with a gene, differing through initiation, RNA splicing, end formation or other processing. Different transcript isoforms need not encode different proteins.